Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs

Archives of Cardiovascular Diseases

Volumn 102, Issue 1, 2009, Pages 43-50

  Laforest, Laurent ^a   Souchet, Thierry ^b   Moulin, Philippe ^c   Ritleng, Cécile ^a   Desamericq, Gaëlle ^a   Le Jeunne, Philippe ^d   Schwalm, Marie Sophie ^d   Van Ganse, Eric ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

^b Dohme Chibret Centre de Recherche Riom   (France)

^c LOUIS PRADEL HOSPITAL   (France)

^d Cehedim Strategic Data   (France)

Author keywords

Fibrate; HDL cholesterol; Prevention; Primary care; Statin; Triglyceride

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ATORVASTATIN; BENFLUOREX; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 63049122871     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.06.021     Document Type: Article

References (23)

1. Therapeutic Management of dyslipidemic patients: guidelines, French Health Products Safety Agency (Afssaps), Saint-Denis, France updated 2005 http://www.afssaps.sante.fr. (Visited on 22 December 2008).
2. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143-421.
3. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: The return on expenditure achieved for lipid therapy (REALITY) study. Curr Med Res Opin 2005;21:1389-99.
4. Jeppesen J, Hein HO, Suadicani P. Relation of high triglyceride-low HDL-chotesterol and LDL-cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997;17: 1114-20.
5. Burchfiel CM, Laws A, Benfante R, Goldberg RJ. Combined effects of HDL-cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation 1995;92:1430-6.
6. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis 1996;119:235-45.
7. Ferrières J, Ruidavets JB, Perret B. Prevalence of dyslipidaemia in a representative sample of the French population. Arch Mal Coeur Vaiss 2005;98:127-32.
8. Van Ganse E, Laforest L, Burke T. Mixed dyslipidemia in patients using lipidlowering therapy in French general practice: a cross-sectional study. Clin Ther 2007;29:1671-81.
9. Laforest L, Moulin P, Souchet T et al. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. Atherosclerosis 2008;199:368-77.
10. De Backer G, Ambrosioni E, Borch-Johnsen K, Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-10.
11. Wilson PF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannet WB, Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
12. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-34.
13. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: Data from a pan-European survey. Diabet Med 2007;24:388-91.
14. Connelly PW, Petrasovits A, Stachenko S, MacLean DR, Little JA, Chockalingam A. Prevalence of high plasma triglyceride combined with low HDL-cholesterol levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-cholesterol levels in the Canadian population. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999;15:428-33.
15. Niessner A, Hofmann R, Kypta A, et al. Low HDL-cholesterol predicts cardiovascular events after carotid stenting: a long-term survey. J Thromb Haemost 2007;5:950-4.
16. Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006;151:755e.1-.e6.
17. Giorda CB, Avogaro A, Maggini M, The DAI Study Group. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007;38:1154-60.
18. Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL. HDL-cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circulation 2000;102:III90-4.
19. Gotto Jr AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002;144:S33-42.
20. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008;10:386-90.
21. Ekelund U, Franks PW, Sharp S, Brage S, Wareham NJ. Increase in physical activity energy expenditure is associated with reduced metabolic risk independent of change in fatness and fitness. Diabetes Care 2007;30:2101-6.
22. Aadahl M, Kjær M, Jørgensen T. Associations between overall physical activity level and cardiovascular risk factors in an adult population. Eur J Epidemiol. 2007;22:369-78.
23. Halverstadt A, Phares DA, Wilund KR, Goldberg AP, Hagberg JM. Endurance exercise training raises high-density lipoprotein cholesterol and lowers small low-density lipoprotein and very low-density lipoprotein independent of body fat phenotypes in older men and women. Metabolism 2007;56: 444-50.